Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Kevin Spain, a director of Doximity, Inc. (DOCS), received 3,221 restricted stock units (RSUs) on 08/28/2025 as compensation under the company’s non-employee director policy. Each RSU converts to one share of Class A common stock and vests in full on the earlier of the first anniversary of the grant or the next annual meeting, subject to continued service. After the grant Mr. Spain directly beneficially owned 9,581 Class A shares, which includes 3,221 RSUs and 6,360 previously vested shares. He also has indirect holdings of 244,607 shares in The Kevin Spain Family Trust and 387,500 shares held by Emergence Capital Opportunity I, L.P., of which he is affiliated; he disclaims beneficial ownership of those indirect holdings except for any pecuniary interest.
Doximity, Inc. (DOCS) filing a Form 144 reports a proposed sale of 6,360 restricted common shares with an aggregate market value of $421,655.28, scheduled approximately for 09/02/2025 on the NYSE. The filing shows the shares were acquired as restricted stock on 08/28/2025 and lists total outstanding common shares of 187,299,459. The filer also disclosed sales during the past three months by Timothy Cabral: 20,000 shares sold on 08/15/2025 for $1,275,566.00 and 10,000 shares sold on 06/25/2025 for $600,000.00. Other customary Form 144 statements and signature cautions are included.
Doximity, Inc. (DOCS) Form 144 notice: An insider proposes to sell 2,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on the NYSE, with an aggregate market value of $133,140.00. The securities were acquired the same day via a stock option exercise and paid in cash. The filer previously sold 2,000 shares on 08/01/2025 for $114,180.00 and 2,000 shares on 07/01/2025 for $121,920.00. The filing includes the required representation that the seller does not possess undisclosed material adverse information.
Doximity, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on August 28, 2025. Stockholders representing 97.51% of the voting power were present, providing a strong quorum for conducting company business.
Two Class I directors, Jeff Tangney and Kira Wampler, were elected to serve until the 2028 annual meeting. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of Doximity’s named executive officers for the fiscal year ended March 31, 2025.
Doximity CFO Anna Bryson reported transactions on 08/26/2025. The filing shows the Reporting Person acquired 40,000 shares of Class A common stock through conversion/exercise and simultaneously sold 40,000 shares pursuant to a Rule 10b5-1 trading plan adopted on 05/27/2025. The sales were executed at a weighted-average price of $66.7561 per share, with sale prices ranging from $66.2250 to $67.2200. Following these transactions the Reporting Person beneficially owns 346,925 shares (direct). The filing also discloses outstanding stock option activity related to 40,000 options with an $8.26 exercise price.
Insider transactions by Doximity director Timothy S. Cabral on 08/15/2025: Mr. Cabral converted 20,000 shares of Class B common stock into Class A shares and exercised 20,000 stock options with a $2.21 exercise price, resulting in 20,000 newly acquired Class A shares. He sold 16,200 Class A shares at a weighted-average price of approximately $63.682 and an additional 3,800 Class A shares at a weighted-average price of approximately $64.1889, under a Rule 10b5-1 trading plan adopted February 13, 2025. After these transactions he directly held 10,160 and 6,360 Class A shares as reported across sales; total Class B and exercised option conversions are noted as convertible to Class A.
Doximity, Inc. reporting person Anna Bryson, Chief Financial Officer, had 5,120 shares of Class A common stock withheld on 08/15/2025 to satisfy tax withholding related to the vesting of previously granted restricted stock units. The shares were withheld at a price of $63.54 per share and do not represent a discretionary sale by the reporting person; they were withheld pursuant to an election previously made by the issuer. After the withholding, the reporting person beneficially owns 346,925 shares of Class A common stock.
Jeffrey Tangney, Chief Executive Officer, Director and >10% owner of Doximity, Inc. (DOCS), reported a non‑discretionary reduction of 7,990 shares of Class A Common Stock on 08/15/2025. The shares were withheld by the issuer at a price of $63.54 per share to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. This withholding was made pursuant to an issuer election and is not a voluntary sale by the reporting person. After the withholding, Mr. Tangney beneficially owned 2,249,058 shares of Class A Common Stock according to the Form 4 filing.
Doximity, Inc. (DOCS) Form 144 notifies the market that a person plans to sell 20,000 shares of Common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,275,566.00 and reports 187,299,459 shares outstanding. The shares to be sold were acquired the same day, 08/15/2025, by stock option exercise from the issuer and paid for in cash. The filer also reported two recent sales in the past three months: 10,000 shares sold on 06/25/2025 for $600,000.00 and 10,000 shares sold on 05/23/2025 for $505,796.00. The signer certifies no undisclosed material adverse information.
Doximity, Inc. announced that its General Counsel, Corporate Secretary, and Chief Compliance Officer, Jennifer Chaloemtiarana, will step down from all three roles effective August 29, 2025, and John Vaughan will assume these positions on the same date.
Chaloemtiarana will continue with the company in an advisory capacity through November 17, 2025, after which she will receive post-employment payments and benefits under her August 10, 2020 offer letter referenced in a prior Form 10-Q filing.